It’s that time of the year. Mike Huckman, CNBC Pharmaceutical Industry Reporter, shares his outlook on the industry as part of CNBC’s top 7 for […]
Top 7 questions for Pharma and Biotech in 2007 Read More »
By Daniel R. Matlis No, it is not a typo. If you are uninsured, that $4 prescription will probably cost you $1,053. Why so much
That will be 1,053 Dollars for your 4 Dollar prescription Read More »
By Daniel R. Matlis No, it’s not what you think; I’m not going “pro” this or “anti” that on you. I am referring to the
My Body, My Choice? Read More »
By Daniel R. Matlis No, it’s not what you think; I’m not going “pro” this or “anti” that on you. I am referring to the
My Body, My Choice? Read More »
Last week, Dr. Andrew von Eschenbach was confirmed by the Senate to head the U.S. Food and Drug Administration. Dr. von Eschenbach is 65-year-old oncologist,
Senate Confirms von Eschenbach as FDA Commissioner Read More »
That’s not just me saying it. Alan Murray, Managing Editor at the Wall Street Journal agrees. In an Interview on CNBC, Mr. Murray said “The Fact
Pharma’s Business Model Doesn’t Seem to Be Working Read More »
by Daniel R. Matlis Recently I attended a Pharmaceutical Industry panel and heard a high ranking industry executive illustrated the beginning of the end for
Are We Witnessing the Beginning of the End for Big Pharma? Read More »
Source: CNBC/The Wall Street Journal Jim Greenwood, president of the Biotechnology Industry Organization, discusses the impact of the election on the Biotechnology Industry in general and stem-cell
The Election's Impact on the Biotech Industry Read More »
BioSP supports the development of Life-Science Companies in the Tri State region (PA, NJ, DE) FOR IMMEDIATE RELEASE CONTACT: Monica Malave Director, Marketing & Communications
Bio Strategy Partners Adds Axendia to Member Roster Read More »
BioSP supports the development of Life-Science Companies in the Tri State region (PA, NJ, DE) FOR IMMEDIATE RELEASE CONTACT: Monica Malave Director, Marketing & Communications
Bio Strategy Partners Adds Axendia to Member Roster Read More »
by Leslie Gladstone Restaino The explosion of Life sciences innovation and the globalization of the marketplace have heightened the importance of intel1ectual property (IP) in
Understanding Your Patent Portfolio, Reducing Risk Through Due Diligence Read More »
by Leslie Gladstone Restaino The explosion of Life sciences innovation and the globalization of the marketplace have heightened the importance of intel1ectual property (IP) in
Understanding Your Patent Portfolio, Reducing Risk Through Due Diligence Read More »
